Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 7, 2013, Pages 1059-1064

  Poon, Li Mei ^a,b   Hamdi, Amir ^a   Saliba, Rima ^a   Rondon, Gabriela ^a   Ledesma, Celina ^a   Kendrick, Monique ^a   Qazilbash, Muzaffar ^a   Hosing, Chitra ^a   Jones, Roy B ^a   Popat, Uday R ^a   Nieto, Yago ^a   Alousi, Amin ^a   Ciurea, Stefan ^a   Shpall, Elizabeth J ^a   Champlin, Richard E ^a   Kebriaei, Partow ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b National University Cancer Institute   (Singapore)

Author keywords

Acute lymphoblastic leukemia; Allogeneic transplantation; Relapse

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; HYDROXYUREA; METHOTREXATE; NELARABINE; PROTEIN TYROSINE KINASE INHIBITOR; STEROID; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADULT DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DONOR LYMPHOCYTE INFUSION; FEMALE; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PALLIATIVE THERAPY; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84879350571     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.04.014     Document Type: Article

References (25)

1. Haïat S., Marjanovic Z., Lapusan S., et al. Outcome of 40 adults aged from18 to 55 years with acute lymphoblastic leukemia treated with double-delayed intensification pediatric protocol. Leuk Res 2011, 35:66-72.
2. DeAngelo D.J., Dahlberg S., Silverman L.B., et al. Amulticenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. ASH Annual Meet Abstr 2007, 110:587.
3. Bruggemann M., Raff T., Flohr T., et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006, 107:1116-1123.
4. Bassan R., Spinelli O., Oldani E., et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009, 113:4153-4162.
5. Kantarjian H., Thomas D., Jorgensen J., et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study. Lancet Oncol 2012, 13:403-411.
6. Topp M.S., Gökbuget N., Zugmaier G., et al. Long-term follow-up of hematological relapse-free survival in a phase 2 study of blinatumomab in patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (ALL). Blood 2012, 120:5185-5187.
7. Goldstone A.H., Richards S.M., Lazarus H.M., et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008, 111:1827-1833.
8. Cornelissen J.J., van der Holt B., Verhoef G.E., et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood 2009, 113:1375-1382.
9. Spyridonidis A., Labopin M., Schmid C., et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia 2012, 26:1211-1217.
10. National Clinical Practice Guidelines in Oncology (NCCN guidelines) for Acute Lymphoblastic Leukemia2012.
11. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
12. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
13. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
14. Sullivan K.M., Shulman H.M., Storb R., et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981, 57:267-276.
15. Poon L.M., Bassett R., Rondon G., et al. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant 2012, 48:666-670.
16. Lee K.H., Lee J.H., Choi S.J., et al. Bone marrow vs extramedullary relapse ofacute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course. Bone Marrow Transplant 2003, 32:835-842.
17. Shimoni A., Rand A., Hardan I., et al. isolated extra-medullary relapse of acute leukemia after allogeneic stem-cell transplantation; different kinetics and better prognosis than systemic relapse. ASH Annual Meet Abstr 2008, 112:2148.
18. Stadler M., Diedrich H., Dammann E., et al. Extramedullary acute leukemias prior to and after allogeneic hematopoietic stem cell transplantation: a single center study. ASH Annual Meet Abstr 2008, 112:3262.
19. Solh M., DeFor T.E., Weisdorf D.J., Kaufman D.S. Extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation: Better prognosis than systemic relapse. Biol Blood Marrow Transplant 2012, 18:106-112.
20. Higano C.S., Brixey M., Bryant E.M., et al. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transplantation 1990, 50:175-177.
21. Odom L.F., August C.S., Githens J.H., et al. Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man?. Lancet 1978, 2:537-540.
22. Elmaagacli A.H., Beelen D.W., Trenn G., et al. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999, 23:771-777.
23. Alyea E.P., DeAngelo D.J., Moldrem J., et al. NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant 2010, 16:1037-1069.
24. Kantarjian H.M., O'Brien S., Smith T.L., et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. JClin Oncol 2000, 18:547-561.
25. Wiernik P.H., Dutcher J.P., Paietta E., et al. Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: A non-anthracycline containing regimen. Leukemia 1993, 7:1236-1241.